 The study will evaluate the safety and efficacy of Replagal agalsidase alfa at a dose of 0.2 mgkg infused intravenously IV over 40 minutes, every other week. The study will monitor the course of disease in males and females with Fabry disease who are naive to treatment or were previously treated with agalsidase beta Fabrazyme. 